Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2025 May 30;3(2):e100161.
doi: 10.1136/egastro-2024-100161. eCollection 2025.

Dietary convergence induces individual responses in faecal microbiome composition

Affiliations
Comment

Dietary convergence induces individual responses in faecal microbiome composition

Astrid Vermeulen et al. eGastroenterology. .

Abstract

Background: Dietary variation has been identified as a key contributor to microbiome diversification. However, assessing its true impact in a cross-sectional setting is complicated by biological confounders and methodological hurdles. We aimed to estimate the impact of a reduction of dietary variation (dietary convergence) on faecal microbiota composition among individuals consuming a Western-type diet.

Methods: 18 healthy volunteers recruited in the region of Flanders (Belgium) were followed up for 21 days. Participants were allowed to consume their habitual diet during a baseline and follow-up period (7 and 8 days, respectively), intersected by a 6-day intervention during which dietary options were restricted to oat flakes, whole milk and still water. Faecal samples were collected on a daily basis. Quantitative microbiome profiles were constructed, combining 16S rRNA gene amplicon sequencing with flow cytometry cell counting. Blood samples were taken at the beginning and end of each study week.

Results: While the intervention did not affect transit time (as assessed through the analysis of stool moisture), consumption of the restricted diet resulted in an increased prevalence of the Bacteroides2 microbiome community type. Microbial load and Faecalibacterium abundance decreased markedly. Despite dietary restrictions, no convergence of microbial communities (reduction of interindividual and intraindividual variation) was observed. The effect size (ES) of the intervention on genus-level microbiome community differentiation was estimated as 3.4%, but substantial interindividual variation was observed (1.67%-16.42%).

Conclusion: The impact of dietary variation on microbiome composition in a Western population is significant but limited in ES, with notable individual exceptions. Dietary convergence does not invariably translate into interindividual convergence of faecal microbial communities.

Keywords: Diet; Gastrointestinal microbiome; Intestinal microbiota; Microbiota; Nutrients; Prospective studies.

PubMed Disclaimer

Conflict of interest statement

SV-S, JS, JR and GF are listed as inventors on patent WO2019115755A1 ‘A new inflammation-associated, low cell count enterotype’, in the name of VIB VZW, Katholieke Universiteit Leuven, KU Leuven R&D and Vrije Universiteit Brussel, covering the features of the microbiome associated with inflammation. SV-S, SP, JR and GF are credited as inventors on WO2022073973A1 ‘Means and methods to diagnose gut flora dysbiosis and inflammation’, in the name of VIB VZW, Katholieke Universiteit Leuven, KU Leuven R&D and University of Bristol, covering methods to diagnose and treat or reduce the severity of gut microbiota dysbiosis as well as of gastrointestinal inflammation and inflammation-associated disorders or conditions in a subject in need thereof. RYT and JR are included as inventors on the patent application WO2017109059A1, in the name of VIB VZW, Katholieke Universiteit Leuven, KU Leuven R&D and Universiteit Gent covering methods for detecting the presence or assessing the risk of development of inflammatory arthritis disease. SV received financial support for research from AbbVie, J&J, Pfizer, Takeda and Galapagos and speakers’ and/or consultancy fees from AbbVie, Abivax, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Cytoki Pharma, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, IMIDomics, Janssen, J&J, Lilly, Materia Prima, Mestag Therapeutics, MiroBio, Morphic, MRM Health, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Surrozen, Takeda, Theravance, Tillotts Pharma AG, VectivBio, Ventyx, Zealand Pharma. All other authors declare no competing interests.

Figures

Figure 1
Figure 1. Design of The Oatmeal Study. The 21-day study period consisted of a baseline, an intervention and a follow-up phase following an A–B–A reversal design. During the intervention period, participants consumed only oatmeal, whole milk and still water. A food diary was kept throughout the entire study period, and a daily faecal sample was collected. An initial health assessment was performed by a medical practitioner and blood samples were taken on a weekly basis. BMI, body mass index.
Figure 2
Figure 2. Restriction of dietary variation as observed during the intervention period. (A) Principal component analysis of weight-based, food-group-level dietary variation over the study period (Euclidean distance; n=378). Each dot represents the dietary consumption of an individual participant during a day. Ellipses represent the 95% CI of the relevant group. (B) Boxplot presenting dietary variance observed before/after (baseline and follow-up combined) and during the intervention period. Variance significantly decreased during the intervention (n=378; dispersion test on Euclidean distances at food group level). The body of the boxplot represents the first and third quartiles of the distribution, with the median line, and the whiskers extend from the quartiles to the last data point within 1.5 times IQR, with outliers beyond. *Adjusted p value<0.001. (C) Distribution of weight-based average daily consumption of food groups (n=378). CI, confidence interval; IQR, interquartile range; PCA, Principal Component Analysis.
Figure 3
Figure 3. Microbiome variation associated with dietary convergence. (A) Boxplot comparing faecal microbial load variation over study phases. Load decrease during the intervention period (n=266; Kruskal-Wallis with post hoc Dunn test). (B) Weighted distribution of community-type prevalence over study phases. Bact2 prevalence increased significantly on dietary convergence (n=266; online supplemental figure 9). (C) Boxplot representing Faecalibacterium abundance distribution over study phases. A decrease in the abundance was observed during the intervention period (n=266; Kruskal-Wallis with post hoc Dunn test). (D) Boxplot presenting quantitative microbiome variance observed before/after (baseline and follow-up combined) and during the intervention period. Variance significantly increased during the intervention (n=266; dispersion test on Bray-Curtis dissimilarities at genus level). (A–D) Analyses performed excluding lag samples. (A,C,D) The body of the boxplot represents the first and third quartiles of the distribution, with the median line and the whiskers extend from the quartiles to the last data point within 1.5 times IQR, with outliers beyond. *adjP<0.05, **adjP<0.001. adjP, adjusted p value; Bact1, Bacteroides1; Bact2, Bacteroides2; IQR, interquartile range; Prev, Prevotella; Rum, Ruminococcaceae.
Figure 4
Figure 4. Impact of dietary convergence on microbiome diversification. (A) Principal coordinate analysis representing quantitative genus-level microbiome variation (n=381; Bray-Curtis dissimilarity). Arrows on the plot indicate direction and relative magnitude of shifts observed between baseline and intervention (dietary convergence) vs intervention and follow-up (dietary divergence). Microbiome community-type distribution is shown on the insert. Boxplots below axis 1 show the distribution of microbiomes belonging to the different study phases along the principal axis of variation. (B) Distance-based redundancy analysis of the association of potential covariates with quantitative genus-level microbiome variation (n=294). Transparent bars correspond with covariates that, while displaying a significant association in a univariable model, did not contribute significantly to microbiome variation in the stepwise variant. Bact1, Bacteroides1; Bact2, Bacteroides2; HbA1c, haemoglobin A1C; HDL, high-density lipoprotein; Prev, Prevotella; Rum, Ruminococcaceae.

Comment on

Similar articles

References

    1. de Vos WM, Tilg H, Van Hul M, et al. Gut microbiome and health: mechanistic insights. Gut. 2022;71:1020–32. doi: 10.1136/gutjnl-2021-326789. - DOI - PMC - PubMed
    1. Falony G, Vandeputte D, Caenepeel C, et al. The human microbiome in health and disease: hype or hope. Acta Clin Belg. 2019;74:53–64. doi: 10.1080/17843286.2019.1583782. - DOI - PubMed
    1. Vijay A, Valdes AM. Role of the gut microbiome in chronic diseases: a narrative review. Eur J Clin Nutr. 2022;76:489–501. doi: 10.1038/s41430-021-00991-6. - DOI - PMC - PubMed
    1. Falony G, Joossens M, Vieira-Silva S, et al. Population-level analysis of gut microbiome variation. Science. 2016;352:560–4. doi: 10.1126/science.aad3503. - DOI - PubMed
    1. Zhernakova A, Kurilshikov A, Bonder MJ, et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science. 2016;352:565–9. doi: 10.1126/science.aad3369. - DOI - PMC - PubMed

LinkOut - more resources